
Claims


1. Use of a compound of formula (I):



an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and

b) a chemotherapeutic agent or a combination of chemotherapeutic agents in the manufacture of a medicament for sensitizing a cancer patient to chemotherapy.

2. Use according to claim 1, wherein the compound of formula (I) is:



or a pharmaceutically acceptable salt thereof.

3. Use according to claim 1 or 2, wherein the compound of formula (I) is provided as the free base.
4. Use according to any one of claims 1 to 3, wherein the chemotherapeutic agent is selected from the group comprising a platinum based chemotherapeutic, fluorouracil, capecitabine, Raltitrexed, taxol, BGC 945, OSI-7904L and combinations of two or more of the same.
5. Use according to claim 4, wherein the platinum based chemotherapeutic is selected from the group comprising cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, lipoplatin and combinations thereof, in particular cisplatin.
6. Use according to claim 4 or 5 wherein the chemotherapeutic comprises oxaliplatin.
7. Use according to any one of claims 4 to 6, wherein the chemotherapeutic comprises capecitabine.
8. Use according to any one of claims 4 to 6, which comprises 5-FU.
9. Use according to any one of claims 4 to 6 and claim 8, wherein the chemotherapeutic is selected from FOLFOX, FOLFIRI and FOLFIRINOX.
10. Use according to any one of claims 1 to 9, wherein the cancer is an epithelial cancer.

11. Use according to claim 10, wherein the cancer is selected from the group comprising liver cancer, hepatocellular carcinoma, cholangiocarcinoma, biliary tract cancer, breast cancer, prostate cancer, colorectal cancer, ovarian cancer, cervical cancer, lung cancer, gastric cancer, pancreatic, bone cancer, bladder cancer, head and neck cancer, thyroid cancer, skin cancer, renal cancer, and oesophagus cancer.
12. Use according to claim 11, wherein the breast cancer is non-ER+ breast cancer.
13. Use according to claim 11, wherein the cancer is selected from gastric cancer, hepatocellular carcinoma and choloangiocarcinoma.
14 Use according to any one of claims 1 to 13, wherein the cancer is refractory and/or resistant to chemotherapy.
15. Use according to any one of claims 1 to 14, wherein the cancer is HER2 positive or HER2 amplified.
16. Use according to any one of claims 1 to 15, wherein each dose of the compound of formula (I) is in the range 100 to 900mg.
17. Use according to claim 16, wherein each dose is in the range of 300 to 500mg.
18. Use according to claim 17, wherein each dose is 400 mg.
19. Use according to any one of claims 1 to 18, wherein the medicament is to be administered orally.
20. Use according to any one of claims 1 to 19, wherein the medicament is to be administered bi-daily.